Microba Life Sciences Limited (ASX:MAP)

Microba Life Sciences Revenue

In the fiscal year ending June 30, 2026, Microba Life Sciences had annual revenue of 14.76M AUD, down -5.81%. Microba Life Sciences had revenue of 7.44M in the half year ending June 30, 2026, a decrease of -15.64%. That makes Microba Life Sciences the 37,201st largest company in the world by revenue and 672nd in Australia.

• Revenue: 14.76M
• Revenue Growth: -5.81%
• P/S Ratio: 1.66
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 24.51M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Testing Services and Supplements 14.72M 99.7%
• Research & Development 40.79K 0.3%

By Geography

Chart

• Australia 7.04M 47.7%
• United Kingdom 6.09M 41.3%
• Europe 809.09K 5.5%
• United States 550.83K 3.7%
• Ireland 111.12K 0.8%
• United Arab Emirates 109.97K 0.7%
• New Zealand 40.58K 0.3%
• Asia 7.02K 0.0%

Fiscal year ended Jun 30, 2026 See the full Microba Life Sciences breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	14.76M	-910.63K	-5.81%
Jun 30, 2025	15.67M	3.58M	29.60%
Jun 30, 2024	12.09M	6.67M	123.06%
Jun 30, 2023	5.42M	731.49K	15.60%
Jun 30, 2022	4.69M	956.20K	25.62%

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 27, 2026

Data Sources Report a data error